Dr. Khursheed Anwer M.B.A., Ph.D. Net Worth

Dr. Khursheed Anwer M.B.A., Ph.D. biography

Dr. Khursheed Anwer M.B.A., Ph.D. is the Exec. VP & Chief Scientific Officer at Imunon Inc.

What is the salary of Dr D?

As the Exec. VP & Chief Scientific Officer of Imunon Inc, the total compensation of Dr D at Imunon Inc is $484,749. There are 6 executives at Imunon Inc getting paid more, with Michael Tardugno having the highest compensation of $1,694,790.

How old is Dr D?

Dr D is 61, he's been the Exec. VP & Chief Scientific Officer of Imunon Inc since . There are 9 older and 4 younger executives at Imunon Inc. The oldest executive at Imunon Inc is Michael H. Tardugno, 70, who is the Exec. Chairman, Pres & CEO.

What's Dr D's mailing address?

Khursheed's mailing address filed with the SEC is C/O CELSION CORPORATION, 997 LENOX DRIVE, SUITE 100, LAWRENCEVILLE, NJ, 08648.

Insiders trading at Imunon Inc

Over the last 17 years, insiders at Imunon Inc have traded over $895,739 worth of Imunon Inc stock and bought 973,579 units worth $2,229,348 . The most active insiders traders include Gary W Pace, Max Link a Sean F. Moran. On average, Imunon Inc executives and independent directors trade stock every 38 days with the average trade being worth of $22,407. The most recent stock trade was executed by Michael H Tardugno on 12 April 2022, trading 4,000 units of CLSN stock currently worth $14,120.

What does Imunon Inc do?

Celsion is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative cancer treatments, including immunotherapies and DNA-based therapies; and a platform for the development of nucleic acid vaccines currently focused on SARS-CoV2. The company's product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer. ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, is under investigator-sponsored development for several cancer indications. Celsion also has two feasibility stage platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. Both are novel synthetic, non-viral vectors with demonstrated capability in nucleic acid cellular transfection.

Imunon Inc executives and stock owners

Imunon Inc executives and other stock owners filed with the SEC include:

• Michael Tardugno,
  Executive Chairman of the Board, President, Chief Executive Officer
• Michael H. Tardugno,
  Exec. Chairman, Pres & CEO
• Nicholas Borys,
  Senior Vice President and Chief Medical Officer
• Jeffrey Church,
  Chief Financial Officer, Senior Vice President, Corporate Secretary, IR Contact Officer
• Dr. Nicholas Borys,
  Exec. VP & Chief Medical Officer
• Jeffrey W. Church CPA, CPA,
  CFO, Exec. VP & Corp. Sec.
• Dr. Khursheed Anwer M.B.A., Ph.D.,
  Exec. VP & Chief Scientific Officer
• Khursheed Anwer,
  Executive Vice President, Chief Scientific Officer - Nucleic Acid Therapy
• Dr. Khursheed Anwer,
  Exec. VP & Chief Scientific Officer
• Andreas Voss,
  Independent Director
• Alberto Martinez,
  Independent Director
• Robert Hooper,
  Independent Director
• Frederick Fritz,
  Independent Director
• Pok Yu Chow,
  Independent Director
• Donald Braun,
  Independent Director
• Marianne M. Lambertson,
  VP of Communications & Investor Relations
• Timothy J. Tumminello,
  Chief Accounting Officer & Controller
• Sean F. Moran,
  Chief Financial Officer
• Gary W Pace,
  Director
• Stacy Lindborg,
  Director
• Christine A Pellizzari,
  Director
• Timothy J Tumminello,
  Controller
• Inc. Fka Egen, Inc. Egwu,,
  10% owner
• Max Link,
  Director
• Gregory L Weaver,
  Director
• Goff Corinne Le,
  President and CEO
• Constantine John Kardaras,
  Chief Accounting Officer